Insights on the NF-κB system in polycystic ovary syndrome, attractive therapeutic targets
- PMID: 37097332
- DOI: 10.1007/s11010-023-04736-w
Insights on the NF-κB system in polycystic ovary syndrome, attractive therapeutic targets
Abstract
The nuclear factor κappa B (NF-κB) signaling plays a well-known function in inflammation and regulates a wide variety of biological processes. Low-grade chronic inflammation is gradually considered to be closely related to the pathogenesis of Polycystic ovary syndrome (PCOS). In this review, we provide an overview on the involvement of NF-κB in the progression of PCOS particularly, such as hyperandrogenemia, insulin resistance, cardiovascular diseases, and endometrial dysfunction. From a clinical perspective, progressive recognition of NF-κB pathway provides opportunities for therapeutic interventions aimed at inhibiting pathway-specific mechanisms. With the accumulation of basic experimental and clinical data, NF-κB signaling pathway was recognized as a therapeutic target. Although there have been no specific small molecule NF-κB inhibitors in PCOS, a plethora of natural and synthetic compound have emerged for the pharmacologic intervention of the pathway. The traditional herbs developed for NF-κB pathway have become increasingly popular in recent years. Abundant evidence elucidated that NF-κB inhibitors can significantly improve the symptoms of PCOS. Herein, we summarized evidence relating to how NF-κB pathway is involved in the development and progression of PCOS. Furthermore, we present an in-depth overview of NF-κB inhibitors for therapy interventions of PCOS. Taken together, the NF-κB signaling may be a futuristic treatment strategy for PCOS.
Keywords: Cardiovascular disease; Endometrial dysfunction; Hyperandrogenism; Hypothalamic gonadal axis; Insulin resistance; Polycystic ovary syndrome (PCOS); The nuclear factor κB (NF-κB).
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Nuclear factor-κB expression in the endometrium of normal and overweight women with polycystic ovary syndrome.J Obstet Gynaecol. 2017 Oct;37(7):924-930. doi: 10.1080/01443615.2017.1315563. Epub 2017 Jun 15. J Obstet Gynaecol. 2017. PMID: 28617068
-
Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment.Reprod Sci. 2017 May;24(5):682-690. doi: 10.1177/1933719116667218. Epub 2016 Sep 15. Reprod Sci. 2017. PMID: 27634381
-
Upregulation of microRNA-204 improves insulin resistance of polycystic ovarian syndrome via inhibition of HMGB1 and the inactivation of the TLR4/NF-κB pathway.Cell Cycle. 2020 Mar;19(6):697-710. doi: 10.1080/15384101.2020.1724601. Epub 2020 Feb 23. Cell Cycle. 2020. Retraction in: Cell Cycle. 2022 Apr;21(8):878. doi: 10.1080/15384101.2022.2046820. PMID: 32089069 Free PMC article. Retracted.
-
The Novel Insight of Gut Microbiota from Mouse Model to Clinical Patients and the Role of NF-κB Pathway in Polycystic Ovary Syndrome.Reprod Sci. 2024 Nov;31(11):3323-3333. doi: 10.1007/s43032-024-01562-3. Epub 2024 Apr 23. Reprod Sci. 2024. PMID: 38653859 Review.
-
Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).Life Sci. 2019 Jul 1;228:167-175. doi: 10.1016/j.lfs.2019.04.046. Epub 2019 Apr 25. Life Sci. 2019. PMID: 31029778 Review.
Cited by
-
ER stress-induced LINC00173 promotes the apoptosis of ovarian granulosa cells by regulating the HRK/PI3K/AKT pathway in polycystic ovary syndrome.Sci Rep. 2024 Oct 20;14(1):24636. doi: 10.1038/s41598-024-75178-7. Sci Rep. 2024. PMID: 39428498 Free PMC article.
-
Beyond defence: Immune architects of ovarian health and disease.Semin Immunopathol. 2024 Aug 12;46(3-4):11. doi: 10.1007/s00281-024-01021-w. Semin Immunopathol. 2024. PMID: 39134914 Free PMC article. Review.
-
Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice.Drug Des Devel Ther. 2024 Sep 4;18:3925-3938. doi: 10.2147/DDDT.S484531. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39247793 Free PMC article.
-
Exploring the key ingredients and mechanisms of Banxia Xiexin decoction for the treatment of polycystic ovary syndrome based on network pharmacology and experimental validation.Ann Med. 2025 Dec;57(1):2503921. doi: 10.1080/07853890.2025.2503921. Epub 2025 May 15. Ann Med. 2025. PMID: 40375680 Free PMC article.
-
Experimental analysis of acupuncture's effects on hyperandrogenemia and related symptoms in PCOS patients.Front Med (Lausanne). 2025 Jul 24;12:1531506. doi: 10.3389/fmed.2025.1531506. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40776915 Free PMC article. Review.
References
-
- Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, Boyle J, Teede HJ (2022) Polycystic ovary syndrome. Lancet Diabetes Endocrinol 10(9):668–680. https://doi.org/10.1016/S2213-8587(22)00163-2 - DOI - PubMed
-
- Alesi S, Ee C, Moran LJ, Rao V, Mousa A (2022) Nutritional supplements and complementary therapies in polycystic ovary syndrome. Adv Nutr 13(4):1243–1266. https://doi.org/10.1093/advances/nmab141 - DOI - PubMed
-
- Cooney LG, Lee I, Sammel MD, Dokras A (2017) High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 32(5):1075–1091. https://doi.org/10.1093/humrep/dex044 - DOI - PubMed
-
- Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE (2019) The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care 42(4):560–567. https://doi.org/10.2337/dc18-1738 - DOI - PubMed
-
- Joham AE, Piltonen T, Lujan ME, Kiconco S, Tay CT (2022) Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome. Clin Endocrinol (Oxf) 97(2):165–173. https://doi.org/10.1111/cen.14757 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical